The current study identifies ATXN3 as a critical positive regulator for tumor invasion through promoting PD-L1 expression at the transcription level and provides a rationale for targeting this deubiquitinase in antitumor immune therapy. The gene discussed is ATXN3; the disease is neoplasm.